CLINICAL_TRIALS
ClinicalTrials.gov record update
The Norwegian Prednisolone in Early Psychosis Study - NorPEPS. The Role of Immune-modulating Strategies in the Treatment of Psychosis
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03340909
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:33.224910+00:00
- Published At
- 2022-08-01T00:00:00+00:00
- Record Updated At
- 2022-08-01
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Schizophrenia and Related Disorders", "Immune Suppression", "Psychosis", "Cognitive Change"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-08-01"- protocolSection.identificationModule.nctId
"NCT03340909"- protocolSection.identificationModule.officialTitle
"The Norwegian Prednisolone in Early Psychosis Study - NorPEPS. The Role of Immune-modulating Strategies in the Treatment of Psychosis"- protocolSection.statusModule.overallStatus
"TERMINATED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.